1. Healthcare

  2. •

    Medical - Healthcare Information Services
Infinitt Healthcare Co Ltd

Infinitt Healthcare Co Ltd

071200.KS
Infinitt Healthcare Co LtdKR flagKorea Exchange
4,880.00
KRW
+15.00
- -
Infinitt Healthcare Co Ltd
071200.KS
(Korea Exchange)

Recent

price

4,880.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,109.15
4,584.04
3,321.91
2,654.67
2,581.82
2,535.23
2,927.86
2,967.62
2,634.49
3,043.54
2,872.84
3,205.26
3,355.15
3,520.86
3,926.46
4,199.68
4,513.18
Revenue per Share
224
-133.65
-284
367
91
232
291
63
202
297
274
929
5
675
1,550
1,083
1,667.1
Basic EPS, GAAP
-366.06
-178.39
-253.24
161.78
53.39
203.54
158.95
244.7
253.74
-87.34
608.08
616.49
312.66
389.51
469.77
543.76
666.08
Free Cash Flow per Basic Share
- -
25.95
1.23
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
99.96
- -
Dividend per Share
1,188.79
962.85
661.73
1,031.92
1,123.94
1,353.26
1,642.15
1,698.27
1,904.24
2,201.72
2,476.42
3,401.9
3,177.97
4,079.48
5,624.49
6,613.77
7,055.6
Book Value per Share
2,024.9
1,742.42
1,381.04
1,656.15
1,767.76
2,166.31
2,546.05
2,658.38
3,000.35
3,408.51
3,681.71
4,591.4
4,316.4
5,337.59
6,985.38
7,947.27
8,366.97
Tangible Book Value per Share
22
24
24
24
24
24
24
25
24
24
24
24
26
24
24
24
24
Basic Weighted Avg Shares
47,019
109,527
81,135
64,611
62,780
61,795
71,498
72,774
64,315
74,267
70,069
78,170
88,286
85,860
95,750
102,392
110,023
Sales/Revenue/Turnover
13.09
-0.14
-5.86
3.94
4.9
7.18
9.28
7.62
3.66
9.52
10.4
9.49
8.92
4.59
8.07
13.88
18.99
Operating Margin (%)
2,504
3,938
3,881
2,525
3,664
3,576
3,348
3,214
2,691
2,544
2,130
2,360
2,561
2,498
2,594
2,335
2,274
Depreciation Expense
4,994
-3,193
-6,936
8,932
2,213
5,655
7,106
1,545
4,931
7,247
6,683
22,656
132
16,461
37,798
26,405
40,641
Net Income, GAAP
15.48
- -
- -
9.83
33.69
11.16
- -
25.26
9.1
6.11
19.79
13.01
- -
18.41
15.63
24.3
17.23
Effective Tax Rate (%)
10.62
-2.92
-8.55
13.82
3.52
9.15
9.94
2.12
7.67
9.76
9.54
28.98
0.15
19.17
39.48
25.79
36.94
Profit Margin (%)
26,069
24,724
14,125
25,646
27,829
39,537
46,107
50,969
57,954
51,713
59,962
84,504
84,295
107,773
148,525
177,704
188,014
Working Capital
2,315
3,929
3,791
2,500
1,951
25
- -
- -
- -
1,739
1,377
966
2,198
1,670
1,552
788
674
LT Debt
50,561
51,423
45,191
53,546
56,059
61,862
69,527
70,578
76,947
84,310
90,830
113,297
114,837
131,350
171,386
194,692
204,892
Total Equity
10.35
- -
- -
3.73
3.22
5.99
- -
5.52
2.81
8.23
6.64
6.3
- -
2.64
4.3
5.88
9.12
Return on Invested Capital (%)
16.04
- -
- -
26.46
7.64
15.56
- -
3.76
10.78
14.07
11.24
30.35
- -
17.03
30.17
16.85
24.47
Return on Capital (%)
21.5
-12.9
-35.42
43.28
8.44
18.75
19.45
3.78
11.19
14.46
11.71
31.61
0.16
17.98
31.95
17.7
25.65
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,724
1,735
1,875
LT Borrowings
- -
- -
- -
LT Finance Leases
997
788
674
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
199,347
216,760
227,828
Cash, Cash Equivalents & STI
170,590
187,558
192,875
Accounts Receivable, Net
22,473
23,852
28,527
Inventories
1,123
447
1,092
Total Current Liabilities
35,632
39,056
39,815
Payables & Accruals
- -
- -
- -
ST Debt
1,724
1,735
1,875
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.48%
16.91%
13.6%
Free Cash Flow
-88.64%
1.57%
15.73%
Net Income, GAAP
1,285.59%
2,530.02%
-30.14%
Sales/Revenue/Turnover
5.59%
8.04%
6.94%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
21,268
23,833
25,446
24,551
95,750
2025
24,516
25,775
22,081
30,020
102,392
2026
32,148
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
400
335
139
- -
1,550
2025
-43
39.49
583.5
- -
1,083
2026
541
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
99.96
2026
- -
- -
- -
- -
- -
Similar Companies
MultiPlan Corporation (MPLN-WT)
IQ-AI Limited (IQAI.L)
Think Research Corporation (THKKF)
FINDEX Inc. (3649.T)
BrightSpring Health Services, Inc. Tangible Equity Unit (BTSGU)
OneMedNet Corporation (ONMD)
Business
INFINITT Healthcare Co Ltd (071200.KS) develops and provides medical imaging and information technology solutions, including PACS systems for radiology, cardiology, radiation oncology, mammography, dentistry, and mobile applications; vendor neutral archive (VNA) technology; 3D and advanced visualization software across major medical departments; clinical information systems; dose monitoring systems; cloud-based and tele-radiology services; digital pathology solutions; enterprise imaging platforms; and consulting, remote monitoring, and data migration services. Headquartered in Seoul, South Korea, and founded in 2002, the company operates globally through subsidiaries and offices in North America, Europe, Japan, China, Taiwan, South East Asia, Indonesia, Vietnam, the Middle East, Africa, the United Kingdom, and Brazil, serving over 6,300 customers in more than 55 countries. Infinitt targets hospitals, clinics, and healthcare providers with its healthcare IT platforms that enable efficient image management, data analytics, AI-supported diagnostics, and multi-disciplinary collaboration. Recent developments include the announcement of next-generation radiology solutions showcased at RSNA 2025, featuring enhancements in radiology PACS, cardiology, oncology, digital pathology, and ophthalmology with cloud options and advanced MDT tools; a strategic partnership with Leafsprout in late 2024 to advance healthcare imaging; expansion of teleradiology sites with Inspire Radiology to 24 locations by end-2025; achievement of HITRUST r2 certification for INFINITT North America in early 2025; and strong recognition in the 2025 KLAS PACS report for customer support and product development.